市场调查报告书
商品编码
1370519
口干症(口干症)治疗市场:2023-2028 年全球产业趋势、份额、规模、成长、机会与预测Xerostomia (Dry Mouth Disease) Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 |
2022年,全球口干症(口干症)治疗市场规模达7.14亿美元。展望未来,IMARC集团预计到2028年市场规模将达到8.93亿美元,2023-2028年复合年增长率(CAGR)为3.6 % 。
口干症或口干是指口腔干燥的症状或感觉,通常是由于唾液量减少引起的。这种情况是由颈部和头部放射性的不利影响、抗焦虑药物的消耗增加、脱水、糖尿病和阿兹海默症引发的。可以在唾液笔或兴奋剂、人工唾液、处方药和家庭疗法(包括喝水和滋润嘴唇)的支持下进行治疗。除此之外,医生对唾液腺的早期诊断以及使用推荐的口腔保湿产品(例如非处方(OTC)漱口水)可以帮助润滑口腔。这些治疗可缓解不适,预防严重併发症,修復味觉障碍,并减轻口臭和味觉障碍。因此,一些医院和诊所使用口干疗法来治疗唾液腺功能下降。
由于放射治疗和化疗的药物副作用,口干的发生率不断增加,特别是在老年人口中,以及对口干缓解产品的需求不断增加,主要推动了市场的成长。此外,一些处方牙膏、维生素软糖和治疗干燥综合症、阿兹海默症和导致口干症的人类免疫缺陷病毒 (HIV) 的药物的使用量不断增加,也是另一个生长诱导因素。与此一致的是,消费者对口干症早期诊断意识的不断提高、医疗保健支出的显着增加以及多样化诊断技术的出现正在推动市场成长。此外,政府为提高消费者对口干症及其症状、原因和治疗的认识而采取的有利倡议正在推动市场成长。除此之外,各种治疗药物的容易取得以及持续的研发(R&D)活动正在为市场创造积极的前景。
The global xerostomia (dry mouth disease) therapeutics market size reached US$ 714 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 893 Million by 2028, exhibiting a growth rate (CAGR) of 3.6% during 2023-2028.
Xerostomia, or dry mouth, refers to symptoms or sensations of oral dryness that are usually caused due to a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, and Alzheimer's disorder. It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips. Apart from this, the early diagnosis of salivary glands by practitioners and the usage of recommended mouth moisturizing products, such as over-the-counter (OTC) rinsing, can assist in lubricating the mouth. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, and mitigate bad breath and taste disorders. Consequently, xerostomia therapeutics are used across several hospitals and clinics to deal with decreased salivary gland function.
The increasing incidences of dry mouth, especially amongst the geriatric population, due to medicine side-effects of radiotherapy and chemotherapy and the rising need for dry mouth relief products are primarily driving the market growth. Additionally, the growing uptake of several prescription-based toothpaste, vitamin gummies, and medicines for treating Sjogren's syndrome, Alzheimer's diseases, and human immunodeficiency virus (HIV) that cause xerostomia is acting as another growth-inducing factor. In line with this, the rising consumer awareness regarding the early diagnosis of xerostomia, significant enhancements in healthcare expenditure, and the advent of diverse diagnostic technologies are propelling the market growth. Moreover, the favorable initiatives being commenced by governments to sensitize consumers regarding the xerostomia disease, its symptoms, causes, and treatments are impelling the market growth. Apart from this, the easy availability of various therapeutic drugs and ongoing research and development (R&D) activities are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global xerostomia (dry mouth disease) therapeutics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, drug type and distribution channel.
Artificial Saliva/Saliva Substitutes
Salivary Stimulants
OTC
Prescription
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).